Aug. 21 at 3:06 AM
$JNJ $SLS Part 3.
$SLS same 3 Top Institutional holders as
$JNJ
Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September 1, 2026. Very interesting Timeline of events.
The latest update to J&J webpages on AML specifically are hard to ignore. So is the fact that the CEO who led AMBRX to a buyout by J&J in March 2024 (for a couple of Billion) was liking at least half a dozen or more of Dr. Stergiou's LinkedIn posts mid 2024-2025. Even with Stifel and all around, personal introductions between companies by a third party respected CEO that J&J already trusted can make a big difference. I truly believe
$JNJ Deal Conversations began at November 2025 JP Morgan 1x1 conference. SELLAS Life Sciences Group participated in one-on-one (1x1) investor meetings at the J.P. Morgan U.S. Opportunities Forum on Wednesday, November 12, 2025, held at the Kimpton EPIC Hotel in Miami, FL, led by President and CEO Dr. Angelos Stergiou. ✌️🙏❤️🩹